

[Sulfadoxine + pyrimethamine](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.2. Antimalarial medicines > Medicines for chemoprevention](#)

ATC codes: [P01BD51](#)

EMLc

Indication

Malaria ICD11 code: [1F4Z](#)

INN

Sulfadoxine + pyrimethamine

Medicine type

Chemical agent

List type

Core

Additional notes

For intermittent preventive treatment of malaria in infants

Formulations

Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet (EMLc)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Sulfadoxine + pyrimethamine](#)

DrugBank

[Sulfadoxine](#),

[Pyrimethamine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to replace the listing for sulfadoxine + pyrimethamine tablets for use in intermittent preventive treatment of malaria in infants with a dispersible tablet formulation of the same strengths.